In this episode of our Exclusively Life Sciences webinar series, our experts from our EU team will share best practices for innovators to protect their competitive advantage when generics enter the market....more
In late 2019, Congress enacted the “CREATES Act”, which established a private right of action in which generic or biosimilar manufacturers may sue an innovator for an injunction and monetary award for not selling samples of...more
9/6/2022
/ Anticompetitive Behavior ,
Biosimilars ,
Continuing Legal Education ,
CREATE Act ,
Generic Drugs ,
Injunctions ,
Innovator Liability ,
Life Sciences ,
Pharmaceutical Industry ,
Private Right of Action ,
Webinars